In a multi-institutional study published today in Nature Nanotechnology, researchers from The University of Texas MD Anderson Cancer Center reported that engineered bispecific nanobodies successfully strengthened mucosal defenses in the respiratory tract, improving protection against influenza infection and reducing SARS-CoV-2 transmission in vivo.